PARP1 and pancreatic neoplasm: Currently, PARP inhibitors (PARPis) are major players in the first- and later-line therapies for breast, prostate, ovarian and pancreatic cancers [5,7], for which the Food and Drug Administration has approved multiple PARPis for therapies [5].